Article Text

Download PDFPDF
Clinical science
Short term LASIK outcomes using the Technolas 217C excimer laser and Hansatome microkeratome in 46 708 eyes treated between 1998 and 2001
  1. Dan Z Reinstein1,2,3,4,
  2. William B Threlfall5,
  3. Randall Cook5,
  4. Emma Cremonesi6,
  5. Hugo FS Sutton2,
  6. Timothy J Archer1,
  7. Marine Gobbe1
  1. 1London Vision Clinic, London, UK
  2. 2Department of Ophthalmology, University of British Columbia, Vancouver, Canada
  3. 3Department of Ophthalmology, Columbia University Medical Center, New York, USA
  4. 4Centre Hospitalier National d'Ophtalmologie, Paris, France
  5. 5LASIK Vision Corporation, Canada
  6. 6Neovision, Mexico D.F., Mexico
  1. Correspondence to Dr Dan Z Reinstein, London Vision Clinic, 138 Harley Street, London W1G 7LA, UK; dzr{at}


Purpose To report the outcomes of a high-volume, multi-surgeon, multicentre LASIK corporation between 1998 and 2001.

Methods 46 708 eyes of 24 138 consecutive patients with myopic astigmatism had undergone LASIK using the Bausch & Lomb Technolas 217C excimer laser and Hansatome microkeratome. The study included 38 surgeons operating at 11 surgical centres. 31 surgeons underwent standardised training regardless of previous experience, which included didactic, observership and proctorship components. Mean attempted spherical equivalent refraction correction was −4.02±1.93 D (range −0.50 to −12.00 D). Mean attempted cylinder correction was 0.78±0.69 D (range 0.00 to 3.50 D). Median follow-up was 3 months.

Results Postoperative data with at least 1 month follow-up was available in 35 360 eyes (76%) of 18 195 patients. Predictability: mean deviation from intended spherical equivalent refraction correction was −0.21±0.47 D with 81% of eyes within ±0.50 D and 95% of eyes within ±1.00 D. Efficacy: uncorrected distance visual acuity was 20/20 in 71% of eyes and 20/40 in 95% of eyes. Safety: two or more lines of corrected distance visual acuity were lost in 0.57% of eyes. Postoperative corrected distance visual acuity was worse than 20/40 in 0.029% of eyes.

Conclusions The short-term results of a high-volume, multi-surgeon LASIK Corporation were comparable with those reported in the Food and Drug Administration clinical trials during the same period.

  • outcomes
  • excimer
  • cornea
  • epidemiology
  • clinical trial
  • treatment lasers

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Additional appendices are published online only. To view these files please visit the journal online (

  • Linked article YES.

  • Some aspects of this study were presented at the American Society of Cataract and Refractive Surgery Annual Meeting, San Diego, CA, April 28th–May 2nd, 2001.

  • Competing interests None.

  • Patient consent This was a retrospective review of LASIK outcomes.

  • Ethics approval This was a retrospective review of LASIK outcomes.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles